Press Releases Nippon Shinyaku Co., Ltd.

Equities

4516

JP3717600005

Delayed Japan Exchange Other stock markets 10:46:34 13/05/2024 am IST			5-day change	1st Jan Change
3,893 ^JPY	-11.98%		-11.24%	-22.08%

10/04	Jefferies Adjusts Nippon Shinyaku’s Price Target to 5,100 Yen From 6,900 Yen, Keeps at Buy	MT
18/03	Nippon Shinyaku Co., Ltd.(TSE:4516) dropped from S&P Japan Mid Cap 100	CI

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Nippon Shinyaku : Outline of Consolidated Financial Results for the Year Ended March 31, 2024	10/05	PU
Interim report January-March 2024	03/05	AQ
Nippon Shinyaku : Submitted Additional Application of Uptravi® tablets 0.2 mg and 0.4 mg for the Treatment of Pediatric PAH and NDA of Pediatric 0.05 mg formulation to MHLW	16/04	PU
MiNA Therapeutics Enters Research Collaboration with Nippon Shinyaku to Develop RNAa Therapeutics Targeting Rare Neurodegenerative Diseases	05/04	AQ
Nippon Shinyaku : Announcement of Research Alliance with MiNA Therapeutics in the Field of Central Nervous System	04/04	PU
Nippon Shinyaku : UCB Japan Obtained Additional Application of Fintepla® (fenfluramine) for the Treatment of Seizures Associated with Lennox-Gastaut Syndrome in Japan	26/03	PU
Nippon Shinyaku : Vyxeos® Combination for I.V. Injection Receives Approval for the Treatment of High-risk AML in Japan	26/03	PU
Nippon Shinyaku : Announcement of Alliance Agreement for Pirtobrutinib, a Reversible Non-Covalent BTK Inhibitor in Japan	25/03	PU
VILTEPSO® (viltolarsen) injection: Phase II trial (Galactic53 trial) Data presented at the 2024 Muscular Dystrophy Association Clinical & Scientific Conference	06/03	PU
Year-end report 2023	28/02	AQ
Vicore and Nippon Shinyaku Enter into an Exclusive License Agreement to Develop and Commercialize C21 in Japan	09/02	AQ
Nippon Shinyaku : The European Commission Grants Orphan Drug Designation to NS-089/NCNP-02 for the Treatment of Duchenne Muscular Dystrophy	21/12	PU
Nippon Shinyaku : Ending March 2024(FY2023)Presentation Material for IR Meeting (2Q FY2023)(Script+Q&A(Summary))P	07/12	PU
Capricor Therapeutics Announces $23 Million Registered Direct Offering	02/23/02	AQ
The Menarini Group Announces ELZONRIS Designated as an Orphan Drug for BPDCN by Japanese Ministry of Health, Labor and Welfare	31/23/31	AQ
Nippon Shinyaku : Ending March 2024(FY2023)Presentation Material for IR Meeting (1Q FY2023	10/23/10	PU
Nippon Shinyaku : Outline of Consolidated Financial Results for the First Quarter Ende	10/23/10	PU
Nippon Shinyaku : Notice Of Resolutions Of The 160th Annual General Meeting of Shareholders	29/23/29	PU
Nippon Shinyaku : Submission of New Drug Application for NS-87 (daunorubicin and cytarabine liposome injection) in Japan	21/23/21	PU
Nippon Shinyaku : Notice of The 160th Annual General Meeting of Shareholder	02/23/02	PU

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Nippon Shinyaku Co., Ltd.

Equities

4516

JP3717600005

Press Releases

Filters